鼻咽癌的生物靶向治疗进展

李燕巍; 谢广茹; 潘战宇

doi:10.13201/j.issn.1001-1781.2015.07.029

鼻咽癌的生物靶向治疗进展

- 天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室(天津, 300060)

详细信息

通讯作者: 李燕巍,E-mail:liyanwei127@hotmail.com

中图分类号: R739.63

收稿日期: 2014-12-23

Advancement biological target therapy of nasopharyngeal carcinoma

More Information

Corresponding author: LI Yanwei, E-mail: liyanwei127@hotmail.com

Received Date: 23 December 2014

摘要

- 鼻咽肿瘤 /
- 靶向治疗
Abstract: Nasopharyngeal carcinoma(NPC)is one of the most common malignant tumor in China,Southeast Asia and North Africa region.The main treatment of NPC is radiation therapy,and concurrent chemoradiotherapy has become the standard treatment for locally advanced NPC Up to date,the targeted therapy in NPC has been gradually appreciated recently,in this paper,NPC biological targeted therapy in recent years as a progress of treatment were reviewed.
- nasopharyngeal neoplasms /
- targeted therapy

HTML全文

参考文献(26)

[1]	FORASTIERE A,KOCH W,TROTTI A,et al.Head and neck cancer[J].N Engl J Med,2001,345:1890-1900.
[2]	孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社,2009:718-719.
[3]	COHEN E E,LINGEN M W,VOKES E E.The expanding role of systemic therapy in head and neck cancer[J].J Clin Oncol,2004,22:1743-1752.
[4]	GIUSTI R M,COHEN M H,KEEGAN P,et al.FDA review of a panitu-mumab(Vectibix)clinical trial for first-line treatment of metastatic colorectal cancer[J].Oncologist,2009,14:284-290.
[5]	STEWART J S,COHEN E E,LICITRA L,et al.PhaseⅢstudy of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck[J].J Clin Oncol,2009,27:1864-1871.
[6]	LI G,XIE L,ZHOU G,et al.A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients[J].Chin Med J(Engl),2002,115:567-570.
[7]	BIAGI E,DOTTI G,YVON E,et al.Molecular transfer of CD40 and OX40 ligands to leukemichuman B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes[J].Blood,2005,105:2436-2442.
[8]	GROTHEY A,SOBRERO A F,SIENA S.Results of a phaseⅢrandomized,double-blind,placebo-controlled,multicenter trial(CORRECT)of regorafenib plus best supportive care(BSC)versus placebo plus BSC in patients(pts)with metastatic colorectal cancer(mCRC)who have progressed after standard therapies[abstract].J Clin Oncol,2012,30(Suppl 4):LBA385.
[9]	CHUA D T,NICHOLLS J M,SHAM J S.Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy[J].In J Radiat Oncol Biol Phys,2004,59:11-20.
[10]	CHAN A T,HSU M M,GOH B C.Multicenter,phaseⅡstudy of cetuximab in combination with carboplatin in patients with recurrent ormetastatic nasopharyngeal carcinoma[J].J Clin Oncol,2005,23:3568-3576.
[11]	MA B B,KAM M K,LEUNG S F et al.A phaseⅡstudy of concur-rent cetuximab-cisplatin and intensitymodulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma[J].Ann Oncol,2012,23:1287-1292.
[12]	MENG J,GU Q P,MENG Q F,et al.Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma[J].Cell Biochem Biophys,2014,68:181-184.
[13]	郭兵.帕尼单抗联合化疗治疗晚期头颈部肿瘤的研究[J].临床和实验医学杂志,2013,12(22):1811-1814.
[14]	KRISHNA S M,JAMES S,BALARAM P.Expression of VEGF as prognostic-cator in primary nasopharyngeal cancer and its relation to EBV status[J].Virus Res,2006,115:85-90.
[15]	LEE N Y,ZHANG Q,PFISTER D G.Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma(RTOG0615):aphase 2 multi-institutional trial[J].Lancet Oncol,2012,13:172-180.
[16]	YOO D S,KIRKPATRICK J P,CRACIUNESCU O,et al.Prospective trial of synchronous bevacizumab,erlotinib,and concurrent chemoradiation in locally advanced head and neck cancer[J].Clin Cancer Res,2012,18:1404-1414.
[17]	HAINSWORTH J D,SPIGEL D R,GRECO F A.Combined modality treatment with chemotherapy,radiation therapy,bevacizumab,and erlotinib in patients with locally advanced squamous carcinoma of the head and neck:aphaseⅡtrial of the Sarah Cannon oncology researchi consortium[J].Cancer J,2011,17:267-272.
[18]	顾康生,吴秋良,侯景辉.HER-2/neu基因在鼻咽癌中的表达及其临床意义[J].癌症,2001,20(8):869-872.
[19]	DUNGO R T,KEATING G M.Afatinib:first global approval[J].Drugs,2013,73:1503-1515.
[20]	COHEN E E,KANE M A,LIST M A,et al.PhaseⅡtrial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[J].Clin Cancer Res,2005,11:8418-8424.
[21]	SOULIERES D,SENZER N N,VOKES E E.Multicenter phaseⅡstudy of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck[J].J Clin Oncol,2004,22:77-85.
[22]	刘媛,刘东伯,龙国贤,等.吉非替尼和依维莫司对EGFR-TKI耐药鼻咽癌细胞的作用[J].医药导报,2014,33(1):43-48.
[23]	陈楠,张红雨,彭培建,等.顺铂联合吉非替尼对鼻咽癌细胞生长抑制及其机制的探讨[J].中华肿瘤防治杂志,2011,18(8):575-579.
[24]	梁中敏,姚岐,刘维奇,李青.鼻咽癌组织中血管内皮生长因子和生存素的表达[J].中国基层医药,2010,17(11):1480-1482.
[25]	YAN G R,TAN Z,WANG Y.Quantitative proteomics characterization on the antitumor effects of isodeoxyelephantopin against nasopharyngeal carcinoma[J].Proteomics,2013,13:3222-3232.
[26]	LIU M,WANG W,LI X,et al.Wedelia chinensis inhibits nasopharyngeal carcinoma CNE-1cell growth by inducing G2/M arrest in a Chk1-dependent pathway[J].Am J Chin Med,2013,41:1153-1168.